Media Coverage



11/04/2019

Sienna Cancer Diagnostics (ASX:SDX) acquires Sevident


 

 
Sevident CEO Dr Peter French talks about the company's technology and his new role at Sienna Cancer Diagnostics (ASX:SDX) following its acquisition.

 

Jessica Amir: Thanks for tuning into the Finance News Network, I’m Jessica Amir and joining us today from Sevident is CEO Dr Peter French. Hello Peter, nice to chat to you again and welcome back to the network.

 

Dr Peter French: Thanks Jessica, great to be here.

 

Jessica Amir: Peter, just start off by telling us a little bit about your background.

 

Dr Peter French: I guess I’ve got an extensive science and business background. I have a PhD in cell biology and a MBA in technology management, so I’m combining both science and business. And I
suppose I have a track record of successful business creation in the biotech space. Capital raising in the US and I’ve been involved in strategic leadership, of both private and public biotech companies, in Australia and in the US.

 

Jessica Amir: So, Peter, what is the NET technology that Sevident created?

 

Dr Peter French: Sevident was a company that was based on the technology called NET technology, which is a structured complex matrix invented by its founding scientist, Dr Emily Stein. And the really important thing about that is that it is able to capture specifically and rapidly, a range of biological substances that can be used as exquisite diagnostic markers, for cancer and other diseases. So this NET technology is really the basis of several preparations, for a broad range of liquid biopsy applications. And Sevident asked me to become their CEO, late in 2017. And really through my involvement with Sienna Cancer Diagnostics (ASX:SDX), I was able to see that the two companies had a lot in common and that they would benefit from each other’s technologies. And so therefore, the partnership has been completed, with Sienna purchasing the NET technology from Sevident.

 

Jessica Amir: Thanks, Peter. And how will the NET technology be used by Sienna?
 
Dr Peter French: One of the really exciting opportunities in cancer diagnostics, which of course is Sienna’s primary focus, is in a particle called an exosome, which is secreted from cancer cells. And they contain a range of biomarkers that can be highly specific for cancer. But exosomes are really hard to isolate currently. This is where the Sevident NET technology comes in. It can capture exosomes from blood within 30 minutes, is highly scalable, highly efficient and cost effective. And so Sienna sees the NET technology as being an enabler, for a variety of tests for cancer biomarkers, from exosomes and other sources. And it really sees the NET as a platform, on which to develop a range of new diagnostic assays.
 
Jessica Amir: And, Peter, what will your role be at Sienna?
 
Dr Peter French: I’m employed as a strategic technology adviser, which essentially, is involved in finding a variety of new intellectual property that could form the basis, of novel diagnostic assays. And assisting Sienna to expand and develop their portfolio of cancer diagnostics.
 
Jessica Amir: Just lastly, Peter, before we let you go, what are you hoping to achieve at Sienna?
 
Dr Peter French: I’m really excited to join Sienna at this moment in its development, as it aims to become a significant player in the cancer diagnostics globally. And to help the company broaden its range of cancer diagnostic products, whilst remaining focused on its core strategy.
 
Jessica Amir: Dr Peter French, thank you so much for your time.
 
Dr Peter French: Thank you.

03/04/2019

Sienna Cancer Diagnostics to buy San Francisco-based Sevident

Sienna says it will buy the San Francisco-based Sevident for up to $US2.8 million ($A3.95 million) in cash and scrip for its biomarker capture technology.


Sienna said it would pay Sevident $US300,000 up front, provide $US1 million in shares and be eligible to receive milestone payments in cash or scrip up to $US1.5 million.

According to the US Patent and Trademark Office, the technology involved a molecular “net” which was a “three-dimensional matrix comprising capture molecules, linkers and spacers for specific and sensitive analyte capture from a sample”.
Sienna said the technology would be used to develop exosome-based cancer tests.

Sienna said Sevident chief scientist and inventor of the technology Dr Stein would lead development and commercialization of the technology and Sevident chief executive officer, former Benitec chief executive officer, Dr Peter French, would join as an advisor. Sienna was up 0.3 cents or 4.55 percent to 6.9 cents.


02/04/2019

The other ASX health buzz today

 

Just when you thought AirXpanders (ASX:AXP) had turned a corner, they announce another loan covenant breach. Today the company said they were resolving an expect debt covenant breach with “its lender”, although did not specify which lender and how much the debt is for.

 

AirXpanders has been in a bad way for some time: a year ago they ditched the CEO for overspending and not making enough money and has been trying to stem the losses since.

 

The company is up to its third, and possibly last according to their full year report in February, breach waiver with lender Oxford. If you were wondering where the Next Big Thing in med-sci was, Sienna Cancer Diagnostics (ASX:SDX) is looking right at it: exosomes. They’re buying the IP for a tech called NETs to isolate and capture molecular and cellular biomarkers, such as exosomes from small clinical sample volumes. Exosomes are a kind of cellular courier that shuttles genetic information and proteins between cells. Find the ones coming from a cancer and you’ve got a diagnosis.

 

LBT Innovations (ASX:LBT) has started its antibiotic-resistant golden staph trial, the one using its APAS Independence analysis software. The idea is that once the AI-based tech can recognise the nasty bug, that information will be updated into LBT’s software already in use in hospitals. And the WA government is launching a FIFO (fly-in fly-out) mental health code after government-funded research last year found FIFO workers, mostly in the resources sector in that state, experience higher levels of psychological distress than non-FIFO workers.


18/03/2018

Sienna appoints Brazilian distributor

Sienna Cancer Diagnostics (ASX: SDX) has appointed a Brazilian distributor for its breakthrough bladder cancer detection test.

The appointment of Inside Diagnosticos as its exclusive agent selling to pathology labs follows the recent appointments of distributors in Korea and Singapore.

Sienna has the first ever in vitro diagnostic (IVD) for detection of telomerase as an adjunct to urine cytology for assisting the diagnosis of bladder cancer.


 


18/03/2019

Sienna Appoints Exclusive Distribution Partner for Brazil

  • Inside Diagnosticos appointed as exclusive distributor
  • Brazil is a major market with significant opportunity for growth

Melbourne, Australia, 18 March 2019: Sienna Cancer Diagnostics Ltd, (ASX:SDX)("Sienna" or "the Company"), a medical technology company developing and commercialising innovative cancer-related tests, has appointed Inside Diagnosticos as the Company's exclusive distribution partner for Brazil.


18/03/2018

Sienna Signs Inside Diagnosticos as the Brazilian distributor

Sienna says the São Paulo, Brazil-based Inside Diagnósticos will distribute its human telomerase reverse transcriptase (hTERT) bladder cancer adjunct test in Brazil.

Sienna said Inside Diagnósticos would sell the hTERT test to Brazilian pathology labs as an adjunct to urine cytology.

The company said it would work with Inside Diagnósticos to seek regulatory approval from the Brazilian Health Regulatory Agency (Anvisa).Sienna was untraded at six cents.

 


05/02/2018

Sienna Signs Mediwell as Singapore Distributor

Sienna says it has appointed Mediwell Enterprise Pte. Ltd. as a distributor for its telomerase-based cancer diagnostics in Singapore.

Sienna said the agreement would allow Mediwell to sell its in-vitro hTERT adjunct test for bladder cancer to pathology labs and hospitals.

The company said that Mediwell would manage Singapore product approval registration

Sienna was unchanged at 6.4 cents


04/02/2018

Sienna Announces Further Global Expansion with Distributor for Singapore

  • Mediwell Enterprise Pte. Ltd (Mediwell) appointed as distribution partner for Singapore.
  • Singapore has a fast-growing market for in-vitro diagnostic (IVD) tests.

Melbourne, Australia, 04 Feb 2019: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer- related tests, continues expansion into Asia with the signing of distribution partner for Singapore.


04/02/2018

Sienna Diagnostics Inks Singapore Distribution Deal for Bladder Cancer Test

Sienna Cancer Diagnostics said today that it has signed an agreement making Mediwell a non-exclusive distributor of its bladder cancer diagnostic in Singapore.

Sienna's in vitro diagnostic is designed to detect the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer alongside standard urine cytology testing. Under the terms of the deal, Mediwell will offer the test to pathology labs and hospitals in Singapore, as well as be responsible for securing its approval in the country. Sienna will provide training to Singapore-based Mediwell sales, marketing, and technical support staff ahead of product launch.

Additional terms were not disclosed.

Earlier this year, August, Melbourne, Australia-based Sienna inked a distribution agreement for its bladder cancer test in South Korea with Mirax. And last year, it signed on Shaanxi GaoYuan In Vitro Diagnostic Reagents as the exclusive distributor of the test in mainland China.


28/01/2018

Company Shines Through on World Stage

A Scoresby company has developed a test that can help urologists detect bladder cancer earlier. Sienna Cancer Diagnostics is a medical technology company that develops and commercialises cancer related in-vitro diagnostic tests for the pathology laboratory market.


28/01/2018

Sienna Cancer Diagnostics Expands Footprint to Asia as it Looks to Expand Footprint

Australia’s Sienna Cancer Diagnostics is continuing its global expansion plans, having formed partnerships in Korea earlier this month and China about six months earlier.


22/01/2018

Sienna Diagnostics Inks New Distribution Deal for Bladder Cancer Test

Sienna Cancer Diagnostics said today that it has signed a South Korean distribution agreement for its bladder cancer diagnostic with Mirax. Sienna's in vitro diagnostic is designed to detect the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer alongside standard urine cytology testing.


22/01/2018

Sienna Announces Further Global Expansion with Distributor for the Republic of Korea

The distribution agreement provides Mirax Corporation, Ltd. (Mirax) with the right to sell Sienna’s product to Korean pathology laboratories, where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cancer.


22/01/2018

Sienna Appoints Mirax South Korea Cancer Test Distributor

Sienna says it has appointed the Seoul-based Mirax Corp as a distributor for its in-vitro diagnostic for the diagnosis of bladder cancer in South Korea.


22/01/2018

Sienna is Selling its Pee Testers in South Korea to Sniff out Bladder Cancer

Sienna Cancer Diagnostics has expanded into its sixth country, with a South Korean health distributor to sell its cancer detection test in the country.


22/01/2018

Sienna signs new distribution agreement for Korea

Sienna Cancer Diagnostics (ASX:SDX), a medical technology company developing and commercialising cancer-related tests, has signed a new distributor for South Korea.


18/12/2018

Chanticleer CEO poll: Leaders reveal 46 reasons to be cheerful

"Effective healthcare is has become a fundamental expectation in first-world countries, and a core aspirational goal in developing countries. The need to innovate in healthcare, particularly in medical technology, is driven by the dual imperatives of achieving better health outcomes, and increased cost effectiveness of healthcare delivery."

Matthew Hoskin, Sienna Cancer Diagnostics; Australian Financial Review.


07/08/2018

Sienna Announces Exclusive Distribution Partner Appointed for Mainland China

GaoYuan In-Vitro Reagents Co. appointed as exclusive distributor. China is a fast growing consumer of in-vitro diagnostic (IVD) tests. GaoYuan to lead regulatory and approval process with China Food and Drug Administration (CFDA).

 


07/08/2018

Sienna Appoints Exclusive Distribution Partner for mainland China

Sienna announced the appointed Shaanxi GaoYuan In Vitro Diagnostic Reagents Co. (“GaoYuan”) as the Company’s exclusive distribution partner for mainland China.

 


07/08/2018

Sienna Appoints Shaanxi Gaoyuan China Distributor

Sienna says the Xi’an, China-based Shaanxi Gaoyuan In-vitro Diagnostic Reagents Co will distribute its in-vitro adjunct diagnostic for bladder cancer in mainland China.

 


07/08/2018

Sienna Diagnostics Inks Chinese Distribution Deal

Sienna Cancer Diagnostics said today that it has signed on Shaanxi GaoYuan In Vitro Diagnostic Reagents as its exclusive distribution partner in mainland China.

 


18/06/2018

James Mirams, Paradigm Wealth Take 5% Of Sienna

Melbourne’s Paradigm Wealth Management says it has become a substantial shareholder in Sienna with 9,105,829 shares or 5.05 percent.

 


14/06/2018

Investment Administration Services Takes 5% Of Sienna

Investment Administration Services (IAS) says it has become a substantial shareholder in Sienna with 9,105,829 shares or 5.05 percent of the company.

 


14/06/2018

News and Industry Insights

Member News: Johns Hopkins Hospital study of Sienna Cancer Diagnostics IVD test for bladder cancer published.

 


22/05/2018

Sienna Announces R&D Tax Incentive Refund Received

Sienna Cancer Diagnostics Ltd, a medical technology company developing and commercialising innovative cancer-related tests, is pleased to announce the Company has received its R&D Tax Incentive Refund of $631,691 for the 2017 financial year.

 


22/05/2018

Sienna Receives $632k Federal R&D Tax Incentive

Sienna says it has received $631,691 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

 


 

06/04/2018

Mutual Assurance

HR Monthly – Clive Hopkins and Stephanie Wanless

Work Experience: It's a win-win situation. Two SMEs show how much-needed project work has benefitted them and their graduate interns.

Case Study - Sienna Cancer Disgnostics

Education without work experience is kind of like strawberries without cream, or gin without tonic.

 


03/04/2018

How Cycling Helps CEO Matthew Hoskin Come Up With Business Solutions

Interview with Matthew Hoskin for the Life and Leasure section of the Financial Review. Matthew gets in a plug for Sienna and the progress the company has made.

 


13/03/2018

Sienna Cancer Diagnostics Achieves First Sale of Cancer Test in Switzerland

Sienna Cancer Diagnostics Ltd (ASX:SDX) has achieved the first sale of its hTERT cancer test in Switzerland through its distribution partner, Biosystems Switzerland AG.

 


19/02/2018

Sienna Announces StatLab Confident in Growth Trajectory of hTERT Test in USA

StatLab CEO Dan Eckert discusses the US market opportunity for its business, how Sienna’s hTERT product fits into StatLab’s growth strategy, the approach taken by StatLab sales personnel, including hiring the company’s first Advanced Diagnostics Sales Specialist to focus on larger opportunities and increasing industry presence at urology conferences, and the significant interest in the hTERT test shown by pathology laboratories to date.


04-Dec-2017

Sienna Cancer Diagnostics actively seeking acquisitions to drive revenue growth - CEO

Journalist Louise Weihart from the Mergermarket Sydney office: Sienna Cancer Diagnostics [ASX:SDX], an Australian diagnostic technology company, is actively seeking acquisitions to expand its product offering and drive revenue growth, said Chief Executive Officer Matthew Hoskin...



13/11/2017

Johns Hopkins Hospital Study Data to be Presented at USCAP 2018

An abstract discussing the results of a study performed by researchers at The Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States and Canadian Academy of Pathology (USCAP) for presentation at their annual conference in March 2018. 



08/11/2017

John Hopkins completes Sienna bladder cancer test study

Sienna says that Johns Hopkins Hospital has completed a 500-patient study testing of its telomerase-based in-vitro diagnostic for bladder cancer.

Sienna said that the Baltimore, Maryland-based Johns Hopkins Hospital study investigated the presence of human telomerase reverse transcriptase (hTERT) a cancer-related biomarker in urothelial cells.



08/11/2017

Sienna Announces Johns Hopkins Hospital Study Data to be Presented at USCAP 2018

An abstract discussing the results of a study performed by researchers at Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States and Canadian Academy of Pathology (USCAP) for presentation at their annual conference in March 2018.


03/11/2017

Tissue Diagnostics Market Worth 5.14 Billion USD by 2022

New market report released by MarketsAndMarkets lists Sienna Cancer Diagnostics amongst key players in the growing diagnostics market. 


October 2017

Connecting Biotech Students with Industry

Sienna, along with others including CSL, Cell Therapies and Trajan, engaged in student projects as part of the Master of Biotechnology program at University of Melbourne.


18/10/2017

Sienna Cancer Diagnostics, Appendix 4C - Quarterly Cash Flow Report

FNN article covering the release of Sienna's 4C for the quarter ending Sept 2017. The cash balance at 30 September was $4.1 million, with net cash inflow for the quarter totalling $3.4 million. New capital issued through the Company’s IPO contributed $4.4 million during the quarter and receipts from product sales were $243,000.
 


27/09/2017

Sienna Cancer Diagnostics (ASX:SDX) talks IVD test sales

In this interview with Jessica Amir from Finance News Network, Sienna CEO Matthew Hoskin highlights FY17 results and speaks to the process that drove strong sales of Sienna’s in vitro diagnostic (IVD) test. Additionally, he covers the Company’s rising position in the US and European Union markets and outlines future product developments for the organization.


26/09/2017

Sienna appoints exclusive distributor for Denmark and Sweden

Article from Ausbiotech's Biotech Dispatch covering Sienna's distribution agreement with Axlab for Denmark and Sweden. 


25/09/2017

Sienna Diagnostics: Exclusive Distributor Appointed for Denmark and Sweden

Article from BioMelbourne Network describing Sienna's new distribution agreemnt with AxLab


25/09/2017

Sienna Appoints Denmark and Sweden Distributor

In this edition of Morgans Daily, a brief update was provided on Sienna’s appointment of Denmark-based Axlab as the exclusive distributor for its adjunct bladder cancer test in Denmark and Sweden.


25/09/2017

Sienna Cancer Diagnostics Announces Exclusive Distributor Appointed for Denmark and Sweden

On Monday 25 September, Sienna announced that it was delighted with the appointment of Axlab A/S as its exclusive distribution partner for Denmark and Sweden. The agreement provides Axlab with the right to sell Sienna’s product to pathology laboratories where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cancer.


25/09/2017

Sienna Cancer Diagnostics Inks Distribution Agreement with Axlab

On Monday 25 September, Sienna announced that it has entered an agreement that retains Axlab as its exclusive distribution partner for Denmark and Sweden.


25/09/2017

Sienna Cancer Diagnostics to Launch its in-vitro Test in Denmark and Sweden

This article outlines the new distribution agreement in Denmark and Sweden to accelerate the global roll out of Sienna’s hTERT IVD test. Sienna’s test help urologist detect bladder cancer.


25/09/2017

Sienna: Axlab Bladder Test Distributor for Denmark, Sweden

On Monday 25 September, Sienna announced that it was delighted with the appointment of Axlab A/S as its exclusive distribution partner for Denmark and Sweden. This is the first distribution agreement to be signed since Sienna’s ASX listing and will broaden and accelerate the global roll out of its in-vitro diagnostic (IVD) test.


08/09/2017

Daily News on ASX-listed Biotechnology Companies

In this article David Neate, Sienna’s largest shareholder, says he has increased his substantial shareholding in Sienna from 17,002,970 shares (9.43%) to 18,852,970 shares (10.46%). Mr Neate bought 1,850,000 shares on market on August 3 and September 5, 2017 for $296,678 or 16 cents a share.


25/08/2017

Dr Boreham’s Crucible: Sienna Cancer Diagnostics

In this edition of Dr Boreham’s Crucible, Tim Boreham takes a critical look at Sienna’s recent initial public offer while outlining the enormous potential of Sienna’s simple diagnosis tool for pathology labs.


21/08/2017

Sienna Cancer Diagnostics Eyes U.S. for Bladder Cancer IVD following Australian IPO

After raising A$4.6 million through its initial public offering on the Australian Securities Exchange, Sienna Cancer Diagnostics is gearing up to launch the first test to detect telomerase in clinical samples.


31/07/2017

Sienna IPO Raises $4.6m to List on Thursday

Sienna Cancer Diagnostics raised $4.6 million in its initial public offer at 20 cents a share and expects to list on the ASX under the code SDX on Thursday, August 3.


14/07/2017

Sink or Swim podcast: Episode 2 - GetSwift Ltd and Robo 3D Ltd

In this episode of Sink or Swim, OzFinancial CEO Patrick Nelson discusses valuations with Matthew Lindh, Managing Director at Sequoia Corporate Finance. Matthew uses Sienna as an example in his explanation. The Matthew Lindh interview starts at 21:10 into the podcast.

 


30/06/2017

Biotech Company Focused on the Development and Commercialisation of Novel IVD Tests

Australia's Health Professional Radio audio interview with Sienna CEO, Matthew Hoskin in which Sienna's hTERT test is explained to medical professionals.

 

 


20/06/2017

Sienna Cancer Diagnostics not without risk

This article covers Sienna Cancer Diagnostics’ plan to list on the ASX in the following month. Having passed a big hurdle by registering with the US Food & Drug Administration and established distribution partners in the US and Europe, could provide quick access to the Company’s target market.


15/06/2017  

Sienna Develops Early Cancer Detection Test

Sharecafe article talking about the upcoming Sienna IPO and the fact that Sienna is unique among its biotech peers because of existing revenues and regulatory filings.

13/06/2017

 

Sienna Cancer Diagnostics (ASX:SDX) CEO, Matthew Hoskin, discusses its diagnostic technology and upcoming IPO

4-traders article covering Matthew Hoskin's interview with Carolyn Herbert of Finance News Network.

 

 

 


Sign up for updates